Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 101 to 150 of 2518

TitleReference numberPublishedLast updated
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessmentHTE25
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphomaTA1059
Drug-eluting stents for treating coronary artery disease: late-stage assessmentHTE26
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)TA1061
Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessmentHTE24
Suspected cancer: recognition and referralNG12
COVID-19 rapid guideline: managing COVID-19NG191
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19TA878
Slide sheets for moving or repositioning a person: late-stage assessmentHTE23
FallsQS86
Falls: assessment and prevention in older people and in people 50 and over at higher riskNG249
Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and overHST33
Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labourIPG800
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)TA1058
Robot-assisted surgery for soft tissue procedures: early value assessmentHTE21
Robot-assisted surgery for orthopaedic procedures: early value assessmentHTE22
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA1055
Molnupiravir for treating COVID-19TA1056
Relugolix–estradiol–norethisterone for treating symptoms of endometriosisTA1057
Cladribine for treating active relapsing forms of multiple sclerosisTA1053
Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and overTA1054
Early and locally advanced breast cancer: diagnosis and managementNG101
Burosumab for treating X-linked hypophosphataemia in children and young peopleHST8
Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type BHST32
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal)TA1052
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and overTA1051
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and overTA1050
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitableTA1048
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemiaTA1049
Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinomaTA1046
Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)TA1047
Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertensionIPG801
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mitesTA1045
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA1043
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and overTA1044
Advanced breast cancer: diagnosis and treatmentCG81
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancerTA1041
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA1042
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and overTA1033
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and overTA1038
Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and overTA1039
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapyTA1040
Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessmentHTE12
Ovarian cancerQS18
Intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary interventionIPG802
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatmentTA1036
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1037
Tobacco: preventing uptake, promoting quitting and treating dependenceNG209
Epilepsies in children, young people and adultsNG217
Gambling-related harms: identification, assessment and managementNG248

Results per page

  1. 10
  2. 25
  3. 50
  4. All